Intensity Therapeutics reported second quarter 2026 results with a net loss of $3.0 million and cash reserves of $9.5 million as of June 30, 2026. The company raised $1.6 million in net proceeds from its at-the-market facility during the quarter. Clinically, Intensity resumed enrollment for the Phase 3 INVINCIBLE-3 soft tissue sarcoma study and restarted patient treatment in the Phase 2 INVINCIBLE-4 triple-negative breast cancer trial following protocol amendments. The company operates as a late-stage clinical biotechnology firm focused on developing intratumoral cancer therapies.